Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid in Combination With Topical Hydroquinone for Refractory Melasma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Melasma is a common acquired disorder of hyperpigmentaion caused by increased melanin production by melanocytes. Melasma is a name derived from the Greek word melas meaning black.It is characterized by the appearance of brownish or grayish symmetrical patches on sun-exposed skin, most commonly on the face. Compared to men, women are more likely to be affected.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 40
Healthy Volunteers: f
View:
• \- Patients of both sexes with melasma.
Locations
Other Locations
Egypt
Aswan University hospitals
RECRUITING
Aswān
Contact Information
Primary
Heba Allah Mohamed Mustafa, Resident
HebaAllah1704336@aswu.edu.eg
+201151182890
Backup
Moustafa Adam Ali El Taieb, professor
moustafa.eltaib@aswu.edu.eg
+201092991101
Time Frame
Start Date: 2024-06-01
Estimated Completion Date: 2025-06-10
Participants
Target number of participants: 45
Treatments
Active_comparator: Group A
About 15 cases will receive sessions with fractional Er: YAG laser every 3 weeks followed by application of topical 4% (HQ) cream.
Active_comparator: Group B
About 15 cases will receive sessions of intradermal injection of tranexamic acid on the melasma site every 3 weeks concurrently with the application of topical 4% HQ cream every night. The injections will be done using an insulin syringe with a dilution of the tranexamic acid
Active_comparator: Group C
About 15 cases will receive oral tranexamic acid 500mg tablet once daily for three months. And will also be asked to apply a thin layer of topical HQ 4% cream on the hyperpigmented areas once every night.
Related Therapeutic Areas
Sponsors
Collaborators: Aswan University
Leads: Egymedicalpedia